Align Technology (ALGN) Stock News

Align Technology (NASDAQ:ALGN) hosted its 2025 Global Faculty Meeting, bringing together over 100 Invisalign® and iTero™-trained doctor educators for comprehensive education workshops. The event, themed "Innovate. Collaborate. Educate.," focused on Align's latest innovations, clinical evidence, and best practices for treating patients of all ages.

Key highlights include the launch of a new clinical evidence webpage featuring 800+ peer-reviewed publications, expansion of the Align Global Gallery™ to over 1,500 case studies, and the continuation of the research awards program, which has provided $4 million in grants since 2010. The meeting featured presentations on patient demand, practice growth, clinical insights, and case discussions, reinforcing Align's commitment to advancing digital orthodontics and dentistry.

Align Technology (Nasdaq: ALGN) has filed a complaint with the U.S. International Trade Commission (ITC) against Angelalign Technology for alleged patent infringement related to clear aligner products. The company is seeking both an exclusion order to prevent importation of infringing products and a cease-and-desist order to stop sales of existing products in the U.S. market.

This legal action follows previous patent infringement litigation filed in August across multiple jurisdictions including the U.S. District Court, China Intermediate People's Court, and European Unified Patent Court. The complaint alleges that Angelalign's products unauthorized incorporate Align's patented technologies.

Align Technology (NASDAQ:ALGN) hosted its 2025 Invisalign® GP Summit, bringing together over 700 doctors and practice team members for a three-day educational event. The summit showcased the latest innovations in digital orthodontics, including the Invisalign® System, iTero™ scanners, and the Align™ Digital Platform.

The event featured an Innovation Hub demonstrating new technologies like the iTero Lumina™ intraoral scanner, Invisalign® Smile Video, and Align™ X-ray Insights. Align also launched the Women's Smile Collective initiative to support women in dentistry and celebrated the milestone of 20 million Invisalign® smiles transformed.

Align Technology (NASDAQ: ALGN), a leading medical device company specializing in clear aligners and digital dentistry solutions, has announced its participation in three upcoming financial conferences in September 2025.

The company's executives, including EVP Global Finance and CFO John Morici and VP Finance Shirley Stacy, will present at the 2025 Wells Fargo Healthcare Conference (Sept 3), Morgan Stanley 23rd Annual Global Healthcare Conference (Sept 9), and Baird Global Healthcare Conference (Sept 10). All presentations will be accessible via webcast through Align's Investor Relations website.

Align Technology (NASDAQ:ALGN) has initiated patent infringement lawsuits against Angelalign Technology (6699.HK) in the United States, Europe, and China. The litigation targets alleged infringement of Align's patents covering multilayer aligner materials, treatment planning, and advanced aligner features.

Align emphasizes its significant R&D investment of over $300 million annually and approximately $2 billion since 2001. The company maintains extensive global operations, including clinical treatment planning centers across multiple countries and manufacturing facilities in Mexico, Poland, and China, supporting over 20 million Invisalign® patients treated worldwide.

Align Technology (NASDAQ: ALGN) has announced plans to repurchase $200 million of its common stock through open market transactions under its $1.0 billion stock repurchase program approved in April 2025.

The buyback will be executed through a Rule 10b5-1 trading plan and is expected to be completed by January 2026, funded with cash on hand. As of June 30, 2025, Align had approximately 72.5 million shares outstanding and $901.2 million in cash and cash equivalents.

The company's management emphasizes this decision reflects confidence in their long-term strategy and market opportunity, while maintaining focus on strategic execution and disciplined investments despite macroeconomic uncertainties.

Align Technology (Nasdaq: ALGN) announced that President and CEO Joe Hogan has personally purchased approximately $1 million of Align's common stock. This purchase adds to his previous investments, totaling approximately $8 million in stock purchases since his last sale in 2021.

Hogan emphasized his confidence in Align's long-term value and commitment to increasing shareholder value through strategic investments in growth and next-generation technologies. Despite acknowledging ongoing macroeconomic uncertainties, the company maintains its focus on transforming treatment through its Invisalign® System, iTero™ scanners, and exocad™ software, serving over 286,400 doctor customers and targeting a 600 million consumer market opportunity worldwide.

Align Technology (NASDAQ:ALGN) reported mixed Q2 2025 financial results with total revenues of $1,012.4 million, up 3.4% sequentially but down 1.6% year-over-year. Clear Aligner revenues were $804.6 million, declining 3.3% year-over-year, while Imaging Systems revenues grew 5.6% to $207.8 million.

The company reported Q2 GAAP operating income of $163.0 million with a 16.1% margin, and non-GAAP operating margin of 21.3%. GAAP diluted EPS was $1.72, with non-GAAP EPS at $2.49.

Align announced a restructuring plan including workforce reductions and manufacturing optimization, expecting $150-170 million in one-time charges in H2 2025. The company aims to achieve GAAP operating margins of 13-14% and non-GAAP margins above 22.5% in FY 2025.

Align Technology (NASDAQ:ALGN) has announced the commercial launch of its innovative Invisalign System with mandibular advancement featuring occlusal blocks in Malaysia. This breakthrough technology is designed to treat Class II skeletal malocclusion in growing patients aged 10-16 while simultaneously straightening their teeth.

The new system represents a significant advancement in treating Class II malocclusions, which affect 30-45% of cases globally. The technology features integrated solid occlusal blocks with laser welding for improved durability and engagement, enabling earlier mandibular advancement in cases with deep bite. Key benefits include efficient treatment through a single process, enhanced patient comfort with SmartTrack material, and predictable tooth movement using SmartForce features and SmartStage technology.